An Assessment of Health Status among Medical Research Volunteers Who Served in the Project Whitecoat Program at Fort Detrick, Maryland

Guarantor: COL Phillip R. Pittman, MC USA

Contributors: COL Phillip R. Pittman, MC USA*; Sarah L. Norris, MPH⁺; Kevin M. Coonan, MD*§; Kelly T. McKee, Jr., MD MPH[±]

Between 1954 and 1973, more than 2,000 men entering military service as conscientious objectors participated in Project Whitecoat as medical research volunteers for the Army's biological warfare defense program. An assessment of self-reported, current health status among 358 "exposed" individuals and 164 unexposed control subjects found no conclusive evidence that receipt of investigational agents was related to adverse health outcomes. No differences in current overall health, current exercise levels, self-reported symptoms, and self-reported medical conditions were seen between the study groups. Possible associations were seen between exposure to antibiotics or other biological agents and self-reported asthma (13.0% vs. 2.4%, relative risk [RR] = 6.00, 95% confidence interval [CI] = 1.03-34.90, p = 0.050), as well as between receipt of tularemia vaccine(s) and self-reported asthma (13.3% vs. 2.4%, RR = 6.15, 95% CI = 1.03–36.70, p = 0.049) and increased frequency/severity of headaches (35.6% vs. 18.3%, RR = 2.46, 95% CI = 0.99-6.15, p = 0.074). However, the size of the population under study was insufficient to assert with confidence that these statistical associations are real.

Introduction

U nited States government efforts to counter the threat of biological weapons have their genesis in the War Bureau of Consultation, a commission of the National Academy of Sciences that was formed at the request of Secretary of War Harold Stimson in 1941.¹² This group recommended the urgent creation of a program of research to address the problem of biological warfare and, in 1942, President Roosevelt authorized Mr. Stimson to establish the War Research Service as a unit of the Federal Security Agency for this purpose. The War Research Service, headed by George Merck (president of Merck Pharmaceuticals), immediately undertook a program of study of biological agents, conducted with "utmost secrecy."³

With increasing appreciation of the scope and complexity of a large-scale program of research and development in this area, the War Research Service requested that the U.S. Army Chemical Warfare Service assume responsibility. The initial site selected for the program was Edgewood Arsenal, near Aberdeen, Maryland. In 1943, a small National Guard airfield (Detrick Field) just outside Frederick, Maryland, was purchased by the War Department, and the hub of the operation was moved to the renamed Camp Detrick.

The Office of the Army Surgeon General was involved in the biological warfare research and development program from the time of its inception in 1941, but it was not directly responsible for any activities until 1956, when the U.S. Army Medical Unit at Camp Detrick was activated with a mission to evaluate the threat of biological warfare and to develop appropriate countermeasures.⁴ During the same year, Camp Detrick became Fort Detrick. From that time to the present, Fort Detrick has been the home of the nation's biological warfare defense program. The Army Medical Unit was redesignated the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in 1969. The contributions of USAMRIID and its predecessor to military medical research and national security are legion, and the planned integration of USAMRIID with National Institutes of Health and Department of Homeland Security programs through the formation of a national biodefense campus at Fort Detrick⁵ ensures its future leadership role in this area.

Project Whitecoat was the title given to an Army research program "to use human volunteers in medical studies to evaluate the effect of certain biological pathogens upon humans in an effort to determine the vulnerability to attack with biological agents" (W.S. Augerson, 1976, cited in Ref. 4, p 20). The objectives of the studies involved were to develop medical defenses against biological warfare and included techniques for rapid diagnosis, improved therapeutic and prophylactic agents, and development of vaccines against biological weapons and endemic disease threats. The program evolved after a series of meetings in 1954–1955 between representatives of the Army Surgeon General and the Seventh Day Adventist Church. With the background of the Church's philosophy and practice of medical service and encouragement of noncombatancy and its longstanding cooperation with the military in health and medical practice, Project Whitecoat became an accepted and respected vehicle by which conscientious objectors could serve the nation.4 From its inception in 1954 to its termination in 1973, approximately 2,300 individuals participated in this program, more than 90% of whom were Seventh Day Adventists. The group participated in more than 135 clinical research studies involving exposure to live agents, receipt of investigational vaccines, and studies of metabolic and psychological effects of environmental- and infection-induced stress.^{4,6} Most volunteers participated in at least one project, whereas some participated in several. The current study

^{*}USAMRIID, Fort Detrick, MD 21702-5011.

⁺Science Applications International Corp./USAMRIID, Fort Detrick, MD 21702-5011.

[‡]Camber Corp./USAMRIID, Fort Detrick, MD 21702-5011.

[§]Current address: Department of Medical Informatics, University of Utah School of Medicine, Salt Lake City, UT.

The opinions expressed are those of the authors and should not be construed to represent those of Camber Corp., Science Applications International Corp., the Department of the Army, or the Department of Defense.

Reprints: COL Phillip R. Pittman, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702-5011; e-mail: phillip.pittman@amedd.army.mil.

This manuscript was received for review in February 2004 and was accepted for publication in March 2004.

Report Documentation Page				Form Approved OMB No. 0704-0188		
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.						
1. REPORT DATE 1 MAR 2005			3. DATES COVE	RED		
4. TITLE AND SUBTITLE	141		1 4 1	5a. CONTRACT	NUMBER	
served in Project V	Vhitecoat program a	at Fort Detrick, Mai	yland, Military	5b. GRANT NUN	IBER	
Medicine 170:183	• 187			5c. PROGRAM E	LEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER		
Pittman, PR Norri	s, SL Coonan, KM I	MeKee, KT Jr		5e. TASK NUMBER		
				5f. WORK UNIT	NUMBER	
7. PERFORMING ORGANI United States Arm Fort Detrick, MD	ZATION NAME(S) AND AI y Medical Research	DDRESS(ES) Institute of Infectio	us Diseases,	8. PERFORMING REPORT NUMB RPP-04-213	ORGANIZATION ER	
9. SPONSORING/MONITO	RING AGENCY NAME(S) A	AND ADDRESS(ES)		10. SPONSOR/M	ONITOR'S ACRONYM(S)	
				11. SPONSOR/M NUMBER(S)	ONITOR'S REPORT	
12. DISTRIBUTION/AVAIL Approved for publ	LABILITY STATEMENT ic release, distributi	on unlimited				
13. SUPPLEMENTARY NO	DTES					
14. ABSTRACT Between 1954 and 1973, more than 2000 men entering military service as conscientious objectors participated in Project Whitecoat as medical research volunteers for the Army's biological warfare defense program. An assessment of self-reported, current health status among 358 "exposed" individuals and 164 unexposed control subjects found no conclusive evidence that receipt of investigational agents was related to adverse health outcomes. No differences in current overall health, current exercise levels, self-reported symptoms, and self-reported medical conditions were seen between the study groups. Possible associations were seen between exposure to antibiotics or other biological agents and self-reported asthma (13.0% vs. 2.4%, relative risk [RR] = 6.00, 95% confidence interval [CI] = 1.03-34.90, p = 0.050), as well as between receipt of tularemia vaccine(s) and self-reported asthma (13.3% vs. 2.4%, RR = 6.15, 95% CI = 1.03-36.70, p = 0.049) and increased frequency/severity of headaches (35.6% vs. 18.3%, RR = 2.46, 95% CI = 0.99-6.15, p = 0.074). However, the size of the population under study was insufficient to assert with confidence that these statistical associations are real.						
15. SUBJECT TERMS Whitecoat Project, health status, volunteers, human						
16. SECURITY CLASSIFIC	CATION OF:		17. LIMITATION OF	18. NUMBER	19a. NAME OF	
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified	SAR	6	RESPONSIBLE PERSON	

184

Health Status among Project Whitecoat Volunteers

was designed to assess the long-term effects on the health of these men resulting from their involvement in this vital program.

Methods

Study Design

This was a controlled, unblinded, retrospective, cohort study to assess the health status of individuals who volunteered to participate in Project Whitecoat at Fort Detrick, Maryland, during 1955–1973.

Study Population

Approximately 2,300 men who entered military service and were classified as conscientious objectors participated in Project Whitecoat. Most were assigned to Fort Detrick, Maryland, and individuals there were assigned a variety of duties in support of the medical research efforts at the facility. Some worked as technicians in research laboratories, some worked as hospital corpsmen, and others were assigned predominantly administrative duties and responsibilities. Periodically, the group membership was approached regarding interest in participating as volunteers for clinical research studies. Most studies were related to exposure to infectious diseases, for which volunteers would receive proven therapies and occasionally investigational prophylactic agents (e.g., vaccines).

Subjects for this study were recruited from among the membership of the Project Whitecoat alumni group. A total of 358 men who were exposed to an infectious agent or vaccine (study group) and 164 men who participated in research studies as unexposed control subjects (control group) agreed, after signing a written informed consent agreement, to complete a self-administered questionnaire that inquired about health status, ongoing clinical symptoms and signs, reproductive outcomes, and diseases or conditions diagnosed by competent medical authorities. The study was reviewed and approved by the institutional review board at USAMRIID, as well as by the Human Subjects Research Review Board of the U.S. Army Surgeon General.

Exposure Histories

Records for participation in clinical protocols, including receipt of vaccines and disease-causing agents, were obtained by reviewing archives at USAMRIID. The name and type of study in which each volunteer participated were extracted from these records and entered into an automated database for analysis. A total of 197 volunteers received investigational vaccines. The available data did not allow distinction between live vaccines and killed/toxoid products, nor did they allow enumeration of the numbers of different vaccine candidates involved in testing. Two hundred eleven individuals were exposed to disease-causing agents (some of which might have involved exposure to different strains of a given pathogen), and 46 received antibiotics or other therapeutic agents (in physiological or other studies separate from treatment for exposures in other protocols).

Statistical Analyses

The χ^2 and Fisher exact tests were used to compare proportions and the *t* test was used to compare mean differences between the exposed (study) and control groups. Rate differences between groups were compared with Fisher exact tests adjusted for multiple comparisons using a resampling bootstrap approach (SAS MULTTEST) for sets of related variables (e.g., symptoms, diseases and conditions, and reproductive outcomes). To examine the effect of multiple exposures in the exposed (study) group by itself, logistic regression analysis of the number of studies in which subjects were enrolled was used. To examine the possibility that confounder variables could explain group differences, further analysis was done using logistic regression analysis of demographic variables. Subgroup analysis was conducted based on class of exposure (vaccine, pathogen, or therapeutic agent). Effects of individual agents were assessed; however, sample sizes were insufficient for conclusive results. All analyses used SAS version 8.2 (SAS Institute, Cary, North Carolina).

The statistical power of this study to detect rate differences between groups was assessed using a power analysis program.⁷ With the sample sizes of 358 control subjects and 164 study subjects, with testing at the 5% level of significance (one-tailed), a minimal difference in relative risk (RR) of twofold could be detected with at least 80% probability for rates of health-related outcomes, over a range of background health condition rates for the control subjects.

Results

Study Population Characteristics

Study subjects were male and predominantly (91.0%) Caucasian. The median duration of assignment at Fort Detrick was 2.0 years (range, 0–8 years). The mean age of the population at the time that the survey was performed was 58.4 years (range, 46–79 years); the majority of study subjects were highly educated (58.2% possessed college or graduate degrees). Although 12.8% of those completing surveys were retired at the time of the study, less than one-half (47.9%) were fully employed. No demographic differences were found between subjects who had been exposed to test agents in the course of participation in clinical research studies and those who had served as control subjects for the same studies (Table I).

Eighty-seven percent of the study participants reported their current state of health as good or excellent, and 72.6% claimed to engage in at least some exercise every week. Exposed and control subjects did not differ with regard to current overall health status or current exercise level (Table II).

A relatively small proportion of individuals reported tobacco and/or alcohol use. Only 14.9% of survey respondents admitted to having ever smoked cigarettes, 7.7% to having ever smoked cigars, 7.9% to having ever smoked a pipe, and 1.1% to having ever used chewing tobacco or snuff. Aside from a slightly higher percentage of subjects who had been exposed to test agents claiming to have quit smoking cigarettes, no differences between the exposed and control groups with regard to tobacco and alcohol consumption were evident (Table II).

Exposures

Among the 358 exposed subjects, 303 participated in one study while assigned to Fort Detrick, 75 participated in two studies, 17 participated in three studies, and 1 participated in four studies. Vaccine exposures included Venezuelan equine encephalitis (73 persons), tularemia (45 persons), yellow fever Health Status among Project Whitecoat Volunteers

TABLE I

DEMOGRAPHIC DATA

	Study $(n = 35)$	$\begin{array}{l} \text{Control} \\ \text{(}n = 164 \end{array}$) p^a
Race (%)			
Caucasian	90.8	91.5	0.832
African American	3.6	4.3	
Other	5.3	4.3	
Male	100.0	100.0	NT
Mean age, years (range)	58.4 (47-	-74) 58.5 (46-	79)0.822
Mean time spent at Fort Detrick years (range)	, 1.5 (<1	-8) 1.5 (<1-	3) 0.635
Served in military (%)	100.0	100.0	NT
College degree or higher (%)	55.9	63.4	0.126
Current employment status (%)			
Retired	11.7	15.2	0.145
Employed full-time	51.1	40.9	
Employed part-time	31.0	38.4	
Not working because of disability	5.6	5.5	

^a Tests are two-tailed. NT, not tested.

TABLE II

HEALTH AND BEHAVIORAL CHARACTERISTICS

	Study	Control	
	(n = 358)	(n = 164)	p^a
Current health status (%)			0.375
Excellent	39.4	47.6	
Good	46.6	41.5	
Fair	10.6	9.1	
Poor	2.8	1.8	
Current exercise level (%)			0.579
None	25.4	20.1	
More than 5 times/week	10.9	10.4	
Up to 5 times/week	60.1	65.9	
Disabled	3.1	3.0	
Tobacco history			
Ever smoked cigarettes (%)	14.8	15.2	0.896
No. of packs/day (mean)	1.0	1.5	0.285
No. of years smoked (mean)	10.0	11.8	0.500
Quit (among those ever smoked) (%)	96.2	80.0	0.031
Years since quitting (mean)	23.0	16.5	0.084
Ever smoked pipe (%)	7.5	8.5	0.726
Ever smoked cigars (%)	7.8	7.3	1.000
Ever dipped snuff/used chewing tobacco (%)	1.4	0.6	0.670
Alcohol use, ever drink (%)	15.1	19.5	0.206

a Tests are two-tailed.

(31 persons), Eastern equine encephalitis (29 persons), Western equine encephalitis (28 persons), plague (13 persons), Q fever (11 persons), Rift Valley fever (8 persons), anthrax (7 persons), chikungunya (six persons), and adenovirus (4 persons). Virulent agent exposures included *Coxiella burnetii* (Q fever) (58 persons), sand fly fever (30 persons), staphylococcal enterotoxin B (20 persons), *Francisella tularensis* (tularemia) (11 persons), Venezuelan equine encephalitis (7 persons), and *Pseudomonas* endotoxin (2 persons). Antibiotic and other therapeutic agent exposures included tetracycline (25 persons), amino acids (15 persons), chloramphenicol (4 persons), and tyrosine (4 persons).

Subjects who volunteered to participate in virulent bacterial agent exposure studies (e.g., Q fever or tularemia) also received curative antibiotics during, or at the conclusion of, each project.

Outcomes

Most (87%) study participants reported having had children. The proportions of exposed and control subjects with children were similar (87.4% and 86.0%, respectively). A total of 1,052 children were reported to have been sired by the 522 study participants. The vast majority (92.3%) of these children were reported as normal and healthy. No differences between exposed and control groups in the numbers of children per individual, children with congenital abnormalities, or children with mental retardation were seen (Table III).

No differences between exposed subjects and control subjects were seen with regard to self-reported clinical signs and symptoms or diseases (or other medical conditions) (Tables IV and V). When symptoms and diseases among individuals who had received all vaccines and those who had received all virulent agents were examined separately, there remained no differences between the groups. Asthma was reported more frequently among the group of subjects exposed to all antibiotics or other nonagents than among control subjects (13.0% vs. 2.4%, RR = 6.00, 95% confidence interval [CI] = 1.03–34.9, p = 0.050, after adjustment for multiple comparisons).

Attempts to assess frequencies of clinical signs and symptoms or diseases by individual vaccine, individual virulent agent, and individual antibiotic/other agent exposure yielded numbers too small for meaningful analysis for all except recipients of Venezuelan equine encephalitis vaccine(s), tularemia vaccine(s), or virulent C. burnetii. Among these exposures, a possible association between asthma and receipt of tularemia vaccine(s) was observed (13.3% of vaccinees vs. 2.4% of control subjects, RR = 6.15, 95% CI = 1.03-36.70, p = 0.049, after adjustment for multiple comparisons). In the same cohort, an association with an increased frequency of headaches (never or rarely a problem vs. occasionally or more frequently a problem) among tularemia vaccinees was suggested (35.6% vs. 18.3%), but the difference from control subjects did not reach statistical significance (RR = 2.46, 95% CI = 0.99-6.15, p = 0.074, after adjustment for multiple comparisons). There were no differences in any outcome variables (general health, exercise levels, reproductive outcomes, reported symptoms, or reported medical conditions) between subjects participating in one study and those participating in two or more studies (data not shown).

TABLE III

REPRODUCTIVE OUTCOMES

	Study (<i>n</i> = 358)	Control $(n = 164)$	p^a
No. of children, mean (range)	2.0 (0-7)	2.0 (0-6)	0.502
Had any children	313 (87.4%)	141 (86.0%)	0.647
Had children with birth defects or mental retardation	25 (7.0%)	15 (9.1%)	0.381
No. of children ($N = 1,052$)			
"Normal/healthy"	698 (95.6%)	306 (95.0%)	0.540
With birth/congenital defects	24 (3.3%)	14 (4.3%)	
With mental retardation	8 (1.1%)	2 (0.6%)	

^a Tests are two-tailed.

TABLE IV SELF-REPORTED DISEASES AND CONDITIONS

Condition No. % No. % p^2 Amyloidosis 0 0.0 0 0.0 1.000 Anemia 6 1.7 2 1.2 1.000 Anemia of chronic disease 1 0.3 0 0.0 1.000 Aplastic anemia 0 0.0 0 0.0 1.000 Arthritis 55 15.4 25 15.2 1.000 Asthma 25 7.0 4 2.4 0.165 Atopic dermatitis 2 0.6 2 1.2 1.000 Cancer 26 7.3 17 10.4 1.000 Eczema 13 3.6 5 3.0 1.000 Frequent colds 20 5.6 8 4.9 0.998 Glomerulonephritis 0 0.0 2 1.2 1.000 Godgkin's disease 0 0.0 0 1.000 Hemolytic anemia 0 3		Study		Control			
Amyloidosis00.00.01.000Anemia61.721.21.000Anemia of chronic disease10.300.01.000Aplastic anemia00.000.01.000Arthritis5515.42515.21.000Asthma257.042.40.165Atopic dermatitis20.621.21.000Cancer267.31710.41.000Diabetes mellitus257.01710.41.000Ezzema133.653.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Godpasture's syndrome00.000.01.000Hay fever5515.42615.91.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Imoune complex disease10.300.00.0Luemia00.010.61.000Kidney disease30.831.81.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Parkinson's disease10.3	Condition	No.	%	No.	%	p^{lpha}	
Anemia61.721.21.000Anemia of chronic disease10.300.01.000Aplastic anemia00.000.001.000Arthritis5515.42515.21.000Asthma257.042.40.165Atopic dermatitis20.621.21.000Cancer267.31710.41.000Diabetes mellitus257.01710.41.000Eczema133.653.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Goodpasture's syndrome00.00.01.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Indeficiency anemia10.321.21.000Kidney disease30.831.81.000Low white blood cell count92.521.20.964Lupus00.00.01.0001.000Parkinson's disease30.831.81.000Parkinson's disease30.831.81.000Parkinson's dis	Amyloidosis	0	0.0	0	0.0	1.000	
Anemia of chronic disease 1 0.3 0 0.0 1.000 Aplastic anemia 0 0.0 0 0.0 1.000 Arthritis 55 15.4 25 15.2 1.000 Asthma 25 7.0 4 2.4 0.165 Atopic dermatitis 2 0.6 2 1.2 1.000 Cancer 26 7.3 17 10.4 1.000 Diabetes mellitus 25 7.0 17 10.4 1.000 Ezzema 13 3.6 5 3.0 1.000 Frequent colds 20 5.6 8 4.9 0.998 Glomerulonephritis 0 0.0 2 1.2 1.000 Godpasture's syndrome 2 1.2 1 0.3 1.000 Hemolytic anemia 0 0.0 0 0.0 1.000 Hypertension 78 21.8 41 25.0 1.000 Inmune complex disease 1 0.3 1 0.6 1.000 L	Anemia	6	1.7	2	1.2	1.000	
Aplastic anemia00.000.01.000Arthritis5515.42515.21.000Asthma257.042.40.165Atopic dermatitis20.621.21.000Cancer267.31710.41.000Diabetes mellitus257.01710.41.000Eczema133.653.01.000Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Godpasture's syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Iron deficiency anemia10.300.01.000Multiple myeloma00.010.61.000Iron deficiency10.300.01.000Reukemia00.010.61.000Iron deficiency20.600.01.000Reukemia10.3 </td <td>Anemia of chronic disease</td> <td>1</td> <td>0.3</td> <td>0</td> <td>0.0</td> <td>1.000</td> <td></td>	Anemia of chronic disease	1	0.3	0	0.0	1.000	
Arthritis5515.42515.21.000Asthma257.042.40.165Atopic dermatitis20.621.21.000Cancer267.31710.41.000Diabetes mellitus257.01710.41.000Ezzema133.653.01.000Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Godpasture's syndrome00.000.01.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.00.01.0001.000Neutritis20.600.01.000Neutritis20.60.01.000Neutritis20.60.01.000Neutritis20.60.01.000Nultiple myeloma00.00.01.000	Aplastic anemia	0	0.0	0	0.0	1.000	
Asthma 25 7.0 4 2.4 0.165 Atopic dermatitis 2 0.6 2 1.2 1.000 Cancer 26 7.3 17 10.4 1.000 Diabetes mellitus 25 7.0 17 10.4 1.000 Eczema 13 3.6 5 3.0 1.000 Frequent colds 20 5.6 8 4.9 0.998 Glomerulonephritis 0 0.0 2 1.2 1.000 Goodpasture's syndrome 0 0.0 0.0 1.000 Hemolytic anemia 0 0.0 2 1.2 1.000 Hodgkin's disease 0 0.0 0 0.0 1.000 Immune complex disease 1 0.3 1 0.6 1.000 Indep disease 8 2.2 1.2 1.000 Kidney disease 8 2.2 1.2 0.00 Indep disease 8 2.2 1.2 0.964 Lupus 0 0.0 0 0.0 <td>Arthritis</td> <td>55</td> <td>15.4</td> <td>25</td> <td>15.2</td> <td>1.000</td> <td></td>	Arthritis	55	15.4	25	15.2	1.000	
Atopic dermatitis2 0.6 2 1.2 1.000 Cancer26 7.3 17 10.4 1.000 Diabetes mellitus25 7.0 17 10.4 1.000 Eczema13 3.6 5 3.0 1.000 Erythema nodosum1 0.3 0 0.0 1.000 Frequent colds20 5.6 8 4.9 0.998 Glomerulonephritis0 0.0 2 1.2 1.000 Godpasture's syndrome2 1.2 1 0.3 1.000 Guillain-Barré syndrome2 1.2 1 0.3 1.000 Hardey fever 55 15.4 26 15.9 1.000 Hemolytic anemia0 0.0 2 1.2 1.000 Immune complex disease1 0.3 1 0.6 1.000 Iron deficiency anemia1 0.3 2 1.2 1.000 Kidney disease8 2.2 12 7.3 1.000 Leukemia0 0.0 1 0.6 1.000 Low white blood cell count 9 2.5 2 1.2 0.964 Lupus0 0.0 0.0 1.000 Multiple myeloma0 0.0 0.0 1.000 Neuritis2 0.6 0.0 1.000 Parkinson's disease 3 0.8 3 1.8 1.000 Parkinson's disease 3 0.8 3	Asthma	25	7.0	4	2.4	0.165	
Cancer267.31710.41.000Diabetes mellitus257.01710.41.000Eczema133.653.01.000Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Godpasture's syndrome00.000.01.000Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Leukemia00.010.61.000Lupus00.000.01.000Multiple myeloma00.000.01.000Neuritis20.600.01.000Neuritis20.600.01.000Neuritis20.60.01.000Neuritis20.60.01.000Nitiple sclerosis10.30.01.000Neuritis20.60.01.000Neuritis10.30.01.000Rideer's syndrome<	Atopic dermatitis	2	0.6	2	1.2	1.000	
Diabetes mellitus257.01710.41.000Eczema133.653.01.000Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Goodpasture's syndrome00.000.01.000Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.0001.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Icaukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple sclerosis10.300.00.00Neuritis20.600.01.000Parkinson's disease30.810.61.000Pneumonia4312.02414.61.000Pneumonia10.310.61.000Riter's syndrome10.310.61.000Riter's syndrome10.310.61.000Sarcoidosis	Cancer	26	7.3	17	10.4	1.000	
Eczema133.653.01.000Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Goodpasture's syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.010.00Neuritis20.600.1000Parkinson's disease30.831.81.000Pneumonia4312.02414.61.000Pneumonia4312.02414.61.000Reiter's syndrome10.310.61.000Reiter's syndrome00.00.01.000Sacoidosis20.62 <td< td=""><td>Diabetes mellitus</td><td>25</td><td>7.0</td><td>17</td><td>10.4</td><td>1.000</td><td></td></td<>	Diabetes mellitus	25	7.0	17	10.4	1.000	
Erythema nodosum10.300.01.000Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Goodpasture's syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.0001.000Hypertension7821.84125.01.000Immune complex disease10.321.21.000Iron deficiency anemia10.321.21.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.0001.000Multiple myeloma00.0001.000Nutritis20.600.01.000Parkinson's disease30.81.81.000Pacumonia4312.02414.61.000Pneumonia4312.02414.61.000Sarcoidosis20.621.21.000Sarcoidosis20.621.21.000Sarcoidosis20.60.01.000Reiter's syndrome10.310.61.000Reumatoid arthritis10.3 <t< td=""><td>Eczema</td><td>13</td><td>3.6</td><td>5</td><td>3.0</td><td>1.000</td><td></td></t<>	Eczema	13	3.6	5	3.0	1.000	
Frequent colds205.684.90.998Glomerulonephritis00.021.21.000Goodpasture's syndrome21.210.31.000Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.0000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.20.964Lupus00.010.61.000Low white blood cell count92.521.20.964Lupus00.0001.000Multiple myeloma00.0001.000Nultiple sclerosis10.300.01.000Parkinson's disease30.831.81.000Pneumonita4312.02414.61.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Reiter's syndrome10.310.61.000Reiter's syndrome10.310.61.000Sarcoidosis20.621.21.000Serum s	Erythema nodosum	1	0.3	0	0.0	1.000	
Glomerulonephritis00.021.21.000Goodpasture's syndrome00.000.01.000Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.00.01.000Multiple sclerosis10.30.01.000Neuritis20.600.01.000Patelet problems30.831.81.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Reiter's syndrome00.00.01.000Serum sickness00.00.01.000Siggren's syndrome00.00.01.000Temporal arteritis13.1	Frequent colds	20	5.6	8	4.9	0.998	
Goodpasture's syndrome00.000.01.000Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.00.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.811.61.000Pneumonia4312.02414.61.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Sigern's syndrome00.00.01.000Sigern's syndrome00.00.01.000Sigern's syndrome00.00.01.000Temporal arteritis13.174.31.000Ulcers236.47 <td>Glomerulonephritis</td> <td>0</td> <td>0.0</td> <td>2</td> <td>1.2</td> <td>1.000</td> <td></td>	Glomerulonephritis	0	0.0	2	1.2	1.000	
Guillain-Barré syndrome21.210.31.000Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.321.21.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple sclerosis10.30.01.000Neuritis20.600.01.000Parkinson's disease30.831.810.30.01.0001.000Pneumonia4312.02414.61.000Pneumonia10.3100.00.00.01.000Reiter's syndrome10.3100.00.00.01.000Sacoidosis20.621.210.310.61.000Serum sickness00.00.01.000Carcoidosis20.600.010.310.61	Goodpasture's syndrome	0	0.0	0	0.0	1.000	
Hay fever5515.42615.91.000Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple sclerosis10.300.01.000Multiple sclerosis10.30.01.000Parkinson's disease30.831.81.000Pneumonia4312.02414.61.000Pneumonia4312.02414.61.000Reiter's syndrome10.310.61.000Sacoidosis20.621.21.000Serum sickness00.00.01.000Vargen's syndrome00.00.01.000Vargen's syndrome00.00.01.000Vargen's syndrome00.00.01.000Vargen's granulomatosis00.021.2Vargen's granulomatosis00.00.0 <td< td=""><td>Guillain-Barré syndrome</td><td>2</td><td>1.2</td><td>1</td><td>0.3</td><td>1.000</td><td></td></td<>	Guillain-Barré syndrome	2	1.2	1	0.3	1.000	
Hemolytic anemia00.021.21.000Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.321.21.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.831.81.000Pneumonia4312.02414.61.000Pneumonia10.310.61.000Reiter's syndrome10.310.61.000Sacoidosis20.621.21.000Serum sickness00.000.01.000Vargene's syndrome00.00.01.000Vargene's granulomatosis00.021.2Uretis20.610.61.000Vargene's granulomatosis00.00.01.000Vargene's granulomatosis00.0 </td <td>Hay fever</td> <td>55</td> <td>15.4</td> <td>26</td> <td>15.9</td> <td>1.000</td> <td></td>	Hay fever	55	15.4	26	15.9	1.000	
Hodgkin's disease00.000.01.000Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.831.81.000Pneumonia4312.02414.61.000Pneumonia10.310.61.000Reiter's syndrome10.310.61.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Thyroid disease113.174.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vasculitis00.021.21.000Vasculitis00.00.01.000Total4272221.00.0	Hemolytic anemia	0	0.0	2	1.2	1.000	
Hypertension7821.84125.01.000Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.811.61.000Pneumonia4312.02414.61.000Pneumonia10.310.61.000Reiter's syndrome10.310.61.000Sarcoidosis20.621.21.000Serum sickness00.00.01.0001.000Sijõgren's syndrome00.00.01.000Temporal arteritis13.174.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vasculitis00.021.21.000Vasculitis00.00.01.000Temporal arteritis13.174	Hodgkin's disease	0	0.0	0	0.0	1.000	
Immune complex disease10.310.61.000Iron deficiency anemia10.321.21.000Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Pneumonia4312.02414.61.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vasculitis00.021.21.000Vasculitis00.021.21.000Keiter's granulomatosis00.000.01.000Contral427222221.000	Hypertension	78	21.8	41	25.0	1.000	
Iron deficiency anemia1 0.3 2 1.2 1.000 Kidney disease8 2.2 12 7.3 1.000 Leukemia0 0.0 1 0.6 1.000 Low white blood cell count9 2.5 2 1.2 0.964 Lupus0 0.0 0 0.0 1.000 Multiple myeloma0 0.0 0.0 1.000 Multiple sclerosis1 0.3 0 0.0 1.000 Neuritis2 0.6 0 0.0 1.000 Parkinson's disease3 0.8 3 1.8 1.000 Pneumonia43 12.0 24 14.6 1.000 Pneumonia43 12.0 24 14.6 1.000 Reiter's syndrome1 0.3 1 0.6 1.000 Sarcoidosis2 0.6 2 1.2 1.000 Serum sickness0 0.0 0.0 1.000 Thyroid disease11 3.1 7 4.3 0.938 Uveitis2 0.6 0 0.0 1.000 Vasculitis0 0.0 2 1.2 1.000 Vasculitis0 0.0 2 1.2 1.000 Vasculitis0 0.0 2 1.2 1.000 Vasculitis0 0.0 0.0 1.000 Vasculitis0 0.0 0.0 1.000 Vasculitis0 0.0 0.0 <	Immune complex disease	1	0.3	1	0.6	1.000	
Kidney disease82.2127.31.000Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Patelet problems30.831.81.000Pneumonia4312.02414.61.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.00.01.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vitamin B_{12} deficiency20.610.61.000Wegener's granulomatosis00.000.01.000	Iron deficiency anemia	1	0.3	2	1.2	1.000	
Leukemia00.010.61.000Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Patelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vitamin B_{12} deficiency20.610.61.000Wegener's granulomatosis00.000.01.000	Kidney disease	8	2.2	12	7.3	1.000	
Low white blood cell count92.521.20.964Lupus00.000.01.000Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total4272222222222222	Leukemia	0	0.0	1	0.6	1.000	
Lupus00.000.01.000Multiple myeloma00.00.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Parkinson's disease30.831.81.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.310.61.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.00.01.000Temporal arteritis10.310.61.000Ulcers236.474.30.938Uveitis20.610.61.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Wegener's granulomatosis00.00.00.01.000	Low white blood cell count	9	2.5	2	1.2	0.964	
Multiple myeloma00.000.01.000Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.300.01.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total42722222222222	Lupus	0	0.0	0	0.0	1.000	
Multiple sclerosis10.300.01.000Neuritis20.600.01.000Parkinson's disease30.810.61.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.300.01.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total427222222222222	Multiple myeloma	0	0.0	0	0.0	1.000	
Neuritis20.600.01.000Parkinson's disease30.810.61.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.300.01.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Sjögren's syndrome00.00.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total42722222222222	Multiple sclerosis	1	0.3	0	0.0	1.000	
Parkinson's disease30.810.61.000Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.300.01.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Sjögren's syndrome00.00.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total42722222222222	Neuritis	2	0.6	0	0.0	1.000	
Platelet problems30.831.81.000Pneumonia4312.02414.61.000Pneumonitis10.300.01.000Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Sjögren's syndrome00.00.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.610.61.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total42722222222222	Parkinson's disease	3	0.8	1	0.6	1.000	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Platelet problems	3	0.8	3	1.8	1.000	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Pneumonia	43	12.0	24	14.6	1.000	
Reiter's syndrome10.310.61.000Rheumatoid arthritis41.131.81.000Sarcoidosis20.621.21.000Serum sickness00.000.01.000Sjögren's syndrome00.000.01.000Temporal arteritis10.310.61.000Thyroid disease113.174.31.000Ulcers236.474.30.938Uveitis20.600.01.000Vasculitis00.021.21.000Vitamin B ₁₂ deficiency20.610.61.000Total427222221.0001.000	Pneumonitis	1	0.3	0	0.0	1.000	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Reiter's syndrome	1	0.3	1	0.6	1.000	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Rheumatoid arthritis	4	1.1	3	1.8	1.000	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Sarcoidosis	2	0.6	2	1.2	1.000	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Serum sickness	0	0.0	0	0.0	1.000	
$\begin{array}{c ccccc} Temporal arteritis & 1 & 0.3 & 1 & 0.6 & 1.000 \\ Thyroid disease & 11 & 3.1 & 7 & 4.3 & 1.000 \\ Ulcers & 23 & 6.4 & 7 & 4.3 & 0.938 \\ Uveitis & 2 & 0.6 & 0 & 0.0 & 1.000 \\ Vasculitis & 0 & 0.0 & 2 & 1.2 & 1.000 \\ Vitamin B_{12} \ deficiency & 2 & 0.6 & 1 & 0.6 & 1.000 \\ Wegener's granulomatosis & 0 & 0.0 & 0 & 0.0 & 1.000 \\ Total & 427 & 222 \end{array}$	Sjögren's syndrome	0	0.0	0	0.0	1.000	
$\begin{array}{c cccccc} Thyroid \mbox{disease} & 11 & 3.1 & 7 & 4.3 & 1.000 \\ Ulcers & 23 & 6.4 & 7 & 4.3 & 0.938 \\ Uveitis & 2 & 0.6 & 0 & 0.0 & 1.000 \\ Vasculitis & 0 & 0.0 & 2 & 1.2 & 1.000 \\ Vitamin \mbox{B}_{12} \mbox{deficiency} & 2 & 0.6 & 1 & 0.6 & 1.000 \\ Wegener's \mbox{granulomatosis} & 0 & 0.0 & 0 & 0.0 & 1.000 \\ Total & 427 & 222 \end{array}$	Temporal arteritis	1	0.3	1	0.6	1.000	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Thyroid disease	11	3.1	7	4.3	1.000	
$\begin{array}{cccccc} Uveitis & 2 & 0.6 & 0 & 0.0 & 1.000 \\ Vasculitis & 0 & 0.0 & 2 & 1.2 & 1.000 \\ Vitamin B_{12} \ deficiency & 2 & 0.6 & 1 & 0.6 & 1.000 \\ Wegener's granulomatosis & 0 & 0.0 & 0 & 0.0 & 1.000 \\ Total & 427 & 222 \end{array}$	Ulcers	23	6.4	7	4.3	0.938	
$\begin{array}{ccccc} Vasculitis & 0 & 0.0 & 2 & 1.2 & 1.000 \\ Vitamin B_{12} \ deficiency & 2 & 0.6 & 1 & 0.6 & 1.000 \\ Wegener's granulomatosis & 0 & 0.0 & 0 & 0.0 & 1.000 \\ Total & 427 & 222 \end{array}$	Uveitis	2	0.6	0	0.0	1.000	
$\begin{array}{ccccc} \mbox{Vitamin} \ B_{12} \ deficiency & 2 & 0.6 & 1 & 0.6 & 1.000 \\ \mbox{Wegener's granulomatosis} & 0 & 0.0 & 0 & 0.0 & 1.000 \\ \ Total & 427 & 222 \end{array}$	Vasculitis	0	0.0	2	1.2	1.000	
Wegener's granulomatosis 0 0.0 0 0.0 1.000 Total 427 222 22 222 2 2 2 2 2 2 2 2 2 2 2 2 </td <td>Vitamin B₁₂ deficiency</td> <td>2</td> <td>0.6</td> <td>1</td> <td>0.6</td> <td>1.000</td> <td></td>	Vitamin B ₁₂ deficiency	2	0.6	1	0.6	1.000	
Total 427 222	Wegener's granulomatosis	0	0.0	0	0.0	1.000	
	Total	427		222			

One-tailed Fisher exact test adjusted for multiple comparisons (bootstrap).

Discussion

a

^b Two-tailed Fisher exact test.

Men entering military service between 1955 and 1973 who volunteered to serve at Fort Detrick in Project Whitecoat participated in a wide variety of clinical research studies involving exposure to investigational vaccines, pathogenic agents, other biologicals (such as antibiotics), and environmental stresses, for the purpose of preparing our nation against the threat of biological warfare. Most, but not all, Project Whitecoat participants were members of the Seventh Day Adventist Church. Individu-

als were recruited from the ranks of enlisted soldiers (predominantly draftees) with a 1-A-O (conscientious objector) classification who were engaged in basic or advanced individual training at the Medical Training Center, Fort Sam Houston, Texas. Upon arrival at Fort Detrick, personnel underwent a complete series of medical evaluations (including detailed history, physical examination, and laboratory studies) and then were assigned to a variety of duties within the Medical Research

TABLE	v
SELF-REPORTED	SYMPTOMS

	Study,	Control,	Study,	Control.	
Symptom	No.	No.	%	%	p^a
Arthralgia					
Severe	31	15	8.7	9.1	0.488
Moderate	126	49	35.2	29.9	
Mild/none	201	100	56.1	61.0	
Fatigue					
Severe	26	7	7.3	4.3	0.204
Moderate	100	39	27.9	23.8	01201
Mild/none	232	118	64.8	72.0	
Mvalgia			ono	12.0	
Severe	10	7	2.8	43	0.671
Moderate	80	37	22.3	22.6	0.071
Mild/none	268	120	74.9	73.9	
Insomnia	200	120	74.0	10.2	
Severe	24	12	67	73	0.700
Moderate	97	40	97.1	24.4	0.799
Mild/none	237	112	66.9	60.9	
Depression	201	112	00.2	00.0	
Severe	19	0	26	1.0	0.410
Moderate	52	10	14.0	4.9	0.419
Mild /none	000	100	14.0	11.0	
Memory loss	292	158	81.6	84.1	
Servere	0	-	0.5	0.0	0.000
Severe	9	5	2.5	3.0	0.939
Moderate	51	23	14.2	14.0	
Mild/none	298	136	83.2	82.9	
Abdominal pain					
Severe	4	2	1.1	1.2	0.357
Moderate	46	14	12.8	8.5	
Mild/none	308	148	86.0	90.2	
Headache					
Severe	6	1	1.7	0.6	0.504
Moderate	71	29	19.8	17.7	
Mild/none	281	134	78.5	81.7	
Malaise					
Severe	18	6	5.0	3.7	0.593
Moderate	47	18	13.1	11.0	
Mild/none	293	140	81.8	85.4	
Tremors					
Severe	1	1	0.3	0.6	0.676
Moderate	13	8	3.6	4.9	
Mild/none	344	155	96.1	94.5	
Fevers					
Severe	0	0	0.0	0.0	0.653^{b}
Moderate	17	6	4.7	3.7	
Mild/none	341	158	95.3	96.3	
Rashes					
Severe	4	2	1.1	1.2	0.746
Moderate	31	11	8.7	6.7	
Mild/none	323	151	90.2	92.1	
Comparisons by v^2 f	est excep	t as noted			

Health Status among Project Whitecoat Volunteers

Unit/USAMRIID, such as laboratory technician, animal caretaker, medic, or supply clerk. All duties were noncombatant in nature. All remained full-time soldiers, and most remained at Fort Detrick for the duration of their service obligations. No special consideration or privileges were accorded Project Whitecoat participants.

When volunteers were needed for specific research studies, a briefing to an assembly of Project Whitecoat personnel was provided by the commanding officer, regarding the nature and purpose of the project, the risks involved, and the requirements for each participant. Questions were then entertained. Those expressing interest in participating were subsequently interviewed individually; details of the study were recounted, individuals were allowed to ask questions, and, if the individual again expressed interest in participating, signed consent was obtained (USAMRIID 1969 Fact Sheet, cited in Ref. 8).

During the course of the program, Project Whitecoat volunteers participated in approximately 150 studies.⁸ Although some of the projects remain classified, the vast majority of the work was conducted openly and was reported in the scientific and medical literature. No fatalities directly attributable to participation in these clinical trials occurred. Although the trials met and often exceeded the ethical standards of the day for research involving human subjects, the current clinical research climate would preclude repetition of many of these studies today. The data obtained from research involving Project Whitecoat volunteers therefore stand as unique and represent the only human data available in many areas.

To date, there has been no systematic attempt to assess the long-term impact of these exposures on the health of Project Whitecoat volunteers. In 1991–1992, a questionnaire designed to capture reflections on their experiences, the reasons behind their interest in participating in the program, and demographic profiles was completed by approximately 200 former participants.⁴ One question in this survey addressed potential residual effects of program participation on health. At that time, only one individual in the program had been awarded a service-connected disability designation. A "few" other Project Whitecoat participants cited program participation as a cause of current medical problems; none was confirmed by medical review. 4,8 The current study was an attempt to objectively assess the impact of participation in clinical research studies by the Project Whitecoat population by comparing questionnaire responses from those who were exposed to agents, biologicals, or other potential stressors and those in the program who served as control subjects for the experiments.

Analyses of questionnaires completed by volunteers for this study provided no evidence that exposures sustained by participants in Project Whitecoat were associated with adverse health outcomes. The exposed and control groups were comparable in most demographic and lifestyle parameters. No differences were reported in overall health status between the two groups, and there were no evident effects on reproductive outcomes. Asthma was reported more frequently among subjects exposed to antibiotics or other inert substances than among control subjects, and similar borderline higher frequencies were observed for reported asthma and headaches among subjects exposed to tularemia vaccines. However, the size of the population under study proved insufficient to conclude that these statistical associations were real.

This study has a number of shortcomings. Mortality rates could not be assessed because of incomplete reporting for the total Project Whitecoat population. There are selection and other biases inherent in a volunteer study of this nature, which might have affected our findings. The sample sizes available were insufficient to detect rare health effects. Furthermore, no laboratory studies were performed as part of the study, and no review of medical records was attempted. Therefore, health consequences from exposures experienced by Project Whitecoat participants might have been missed. However, the dearth of evidence suggesting adverse health effects reported by the volunteers who agreed to participate argues against such a possibility.

Project Whitecoat represents an important chapter in the history of medical defense against biological weapons and in human experimentation. The men who volunteered to participate in the seminal studies that provided proof of concept in so many critical areas should be heralded for their contributions to science and medicine in both the military and civilian sectors. It is gratifying that no adverse impact on the overall health of Project Whitecoat volunteers could be conclusively attributed to their participation in these important research studies.

References

- Clendenin RM: Science and Technology at Fort Detrick 1943–1968. Washington, DC, U.S. Army, 1968.
- Smart JK: History of chemical and biological warfare: an American perspective. In: Medical Aspects of Chemical and Biological Warfare, pp 9–85. Edited by Sidell FR, Takafuji ET, Franz DR. Washington, DC, Borden Institute, Walter Reed Army Medical Center, 1997.
- Cole LA: Clouds of Secrecy: The Army's Germ Warfare Tests over Populated Areas. Totowa, NJ, Rowman and Littlefield, 1988.
- Mole RL, Mole DM: For God and Country: Operation Whitecoat: 1954–1973. Brushton, NY, Reach Services, 1998.
- Department of Homeland Security: 2004 Department of Homeland Security Appropriations Act (HR 2555), October 1, 2003.
- Anderson AO: A brief history of military contributions to ethical standards for research involving human subjects. 2003. Available at http://www.geocities. com/artnscience/jm4-primr.html.
- Borenstein M, Rothstein H, Cohen J: Power and Precision. Englewood, NJ, Biostat, 2001.
- Moreno JD: Undue Risk: Secret State Experiments on Humans. New York. NY, W.H. Freeman and Co., 2000.

Copyright of Military Medicine is the property of Association of Military Surgeons of the United States and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.